Galmed Pharmaceuticals (GLMD) to Release Earnings on Monday

Galmed Pharmaceuticals (NASDAQ:GLMD) is scheduled to post its quarterly earnings results before the market opens on Monday, November 5th. Analysts expect Galmed Pharmaceuticals to post earnings of ($0.14) per share for the quarter.

Galmed Pharmaceuticals (NASDAQ:GLMD) last issued its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.01). Galmed Pharmaceuticals had a negative net margin of 1,072.44% and a negative return on equity of 36.66%. The company had revenue of $0.27 million during the quarter, compared to the consensus estimate of $0.27 million. On average, analysts expect Galmed Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of GLMD stock traded up $0.34 during trading on Tuesday, reaching $9.04. The company had a trading volume of 3,135 shares, compared to its average volume of 154,076. Galmed Pharmaceuticals has a one year low of $3.61 and a one year high of $27.06. The company has a market capitalization of $140.63 million, a price-to-earnings ratio of -9.03 and a beta of 2.64.

A number of brokerages recently weighed in on GLMD. ValuEngine downgraded Galmed Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Zacks Investment Research raised Galmed Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 16th. Cantor Fitzgerald set a $59.00 price objective on Galmed Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, October 2nd. Maxim Group cut their price objective on Galmed Pharmaceuticals from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, August 2nd. Finally, Raymond James began coverage on Galmed Pharmaceuticals in a research note on Friday, July 20th. They issued an “outperform” rating and a $26.00 price objective on the stock. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Galmed Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $36.11.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis.

See Also: Using the New Google Finance Tool

Earnings History for Galmed Pharmaceuticals (NASDAQ:GLMD)

Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply